Advanced search

Search our library

European Gram Negative AntiBacterial Engine (ENABLE)
European Commission: Funding opportunities
NIAID: Opportunities & Announcements
REPAIR Impact Fund
CARB-X
Drug Development Process
Tackling the drug-resistance pandemic – 2020 and beyond
Why we need to prioritize developing antibiotics for children
Bringing antimicrobial research and development to Africa – the time is now
The REPAIR Impact Fund: Reflections from the first year
Time to pull out all the stops in the fight against superbugs
Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
Building better breakpoints: data and methods needed to determine breakpoints for new agents
Exploring safety issues in antimicrobial drug development
Moving from preclinical to clinical-stage: Challenges and opportunities
Clinical development of antimicrobials – Phase 1 development challenges
Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
Probability of target attainment analyses for dose selection in antimicrobial drug development
PK/PD murine infection models: Focus on study elements, variability, and interpretation of results
Non-traditional antibacterial therapeutic options and challenges
Testing for the potential of emergence of antimicrobial resistance
Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
Models for antimicrobial R&D: Computational modelling for population PK and PKPD
Enabling academia to fill the discovery gap – Learnings from industry and funders
Infection models for antimicrobial R&D: Intracellular models
Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research
NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
Minimum inhibitory concentration (MIC)
Maximum tolerated dose (MTD)
Investigational new drug (IND)
Epidemiological cut-off value (ECOFF)
Pharmacokinetics-pharmacodynamics (PK/PD)
Tissue concentration
Intracellular concentration
Preclinical development
Median effective dose (ED50)
Toxicity
Target product profile (TPP)
Target candidate profile (TCP)
Pro-drug
Median lethal dose (LD50)
Mechanism of action (MoA)
Cmax
Absorption, distribution, metabolism, elimination (ADME)
Antimicrobial susceptibility testing (AST), resistance testing
PK/PD
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Candidate
Active pharmaceutical ingredient (API)
AntibioticDB